1083 related articles for article (PubMed ID: 30611991)
21. Delivery of therapeutics to the central nervous system.
Chambers JJ
Adv Drug Deliv Rev; 2012 May; 64(7):589. PubMed ID: 22388004
[No Abstract] [Full Text] [Related]
22. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
[TBL] [Abstract][Full Text] [Related]
23. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
Goyal K; Koul V; Singh Y; Anand A
Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
[TBL] [Abstract][Full Text] [Related]
24. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.
Vlieghe P; Khrestchatisky M
Med Res Rev; 2013 May; 33(3):457-516. PubMed ID: 22434495
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
Dilnawaz F; Sahoo SK
Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
[TBL] [Abstract][Full Text] [Related]
26. Differential receptor-mediated drug targeting to the diseased brain.
Rip J; Schenk GJ; de Boer AG
Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
[TBL] [Abstract][Full Text] [Related]
27. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
Banks WA
Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
[TBL] [Abstract][Full Text] [Related]
28. Central nervous system delivery of molecules across the blood-brain barrier.
Gosselet F; Loiola RA; Roig A; Rosell A; Culot M
Neurochem Int; 2021 Mar; 144():104952. PubMed ID: 33400964
[TBL] [Abstract][Full Text] [Related]
29. Implantable and transdermal polymeric drug delivery technologies for the treatment of central nervous system disorders.
Govender T; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Modi G; Naidoo D; Pillay V
Pharm Dev Technol; 2017 Jun; 22(4):476-486. PubMed ID: 27268737
[TBL] [Abstract][Full Text] [Related]
30. Polymeric nanoparticles for drug delivery to the central nervous system.
Patel T; Zhou J; Piepmeier JM; Saltzman WM
Adv Drug Deliv Rev; 2012 May; 64(7):701-5. PubMed ID: 22210134
[TBL] [Abstract][Full Text] [Related]
31. Strategies for transporting nanoparticles across the blood-brain barrier.
Zhang TT; Li W; Meng G; Wang P; Liao W
Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
[TBL] [Abstract][Full Text] [Related]
32. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
Barchet TM; Amiji MM
Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
[TBL] [Abstract][Full Text] [Related]
33. Prodrug approaches to reduce hyperexcitation in the CNS.
Vytla D; Combs-Bachmann RE; Hussey AM; McCarron ST; McCarthy DS; Chambers JJ
Adv Drug Deliv Rev; 2012 May; 64(7):666-85. PubMed ID: 22138074
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.
Bhaskar S; Tian F; Stoeger T; Kreyling W; de la Fuente JM; Grazú V; Borm P; Estrada G; Ntziachristos V; Razansky D
Part Fibre Toxicol; 2010 Mar; 7():3. PubMed ID: 20199661
[TBL] [Abstract][Full Text] [Related]
35. Insights into direct nose to brain delivery: current status and future perspective.
Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
[TBL] [Abstract][Full Text] [Related]
36. Nanoparticles-based delivery system and its potentials in treating central nervous system disorders.
Liu T; Xie Q; Dong Z; Peng Q
Nanotechnology; 2022 Aug; 33(45):. PubMed ID: 35917704
[TBL] [Abstract][Full Text] [Related]
37. Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies.
Khambhla E; Shah V; Baviskar K
Curr Pharm Des; 2016; 22(19):2913-22. PubMed ID: 27033697
[TBL] [Abstract][Full Text] [Related]
38. Nanomaterial applications for neurological diseases and central nervous system injury.
Huang L; Hu J; Huang S; Wang B; Siaw-Debrah F; Nyanzu M; Zhang Y; Zhuge Q
Prog Neurobiol; 2017 Oct; 157():29-48. PubMed ID: 28743465
[TBL] [Abstract][Full Text] [Related]
39. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
[TBL] [Abstract][Full Text] [Related]
40. Nanodelivery systems for overcoming limited transportation of therapeutic molecules through the blood-brain barrier.
Kim KT; Lee HS; Lee JJ; Park EK; Lee BS; Lee JY; Bae JS
Future Med Chem; 2018 Nov; 10(22):2659-2674. PubMed ID: 30499740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
